SNX7886

SNX7886 is a potent, dual-targeting PROteolysis TArgeting Chimera (PROTAC) designed to induce the simultaneous degradation of the Mediator kinases CDK8 and CDK19. Developed by researchers at the University of South Carolina, SNX7886 utilizes a selective CDK8/19 kinase inhibitor warhead conjugated to a cereblon (CRBN)-recruiting ligand. By depleting the CDK8 and CDK19 proteins rather than merely inhibiting their kinase activity, SNX7886 aims to overcome adaptive resistance and achieve more durable transcriptional reprogramming in aggressive leukemias, such as acute myeloid leukemia (AML). In preclinical studies, it demonstrated a DC50 of 10 nM and showed superior growth inhibition compared to traditional kinase inhibitors in refractory AML cell lines like NOMO1.